EVOLVE Short DAPT

Objective

The purpose of this study is to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention(PCI) with SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.

Last Updated: 01/18/2016

Research Study Categories

  • Adult Studies

Specialty

  • Cardiology
Contact
Clinical Trials at 866-839-4128
or clinicaltrials@eirh.org